Cargando…
Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)
BACKGROUND: Acute myeloid leukaemia (AML) with 17p abnormalities (abn(17p)) carries a very poor prognosis due to high refractoriness to conventional chemotherapy, and allogeneic stem cell transplantation (allo-SCT) appears as the only potential curative option. METHODS: To address outcomes after all...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241968/ https://www.ncbi.nlm.nih.gov/pubmed/28100265 http://dx.doi.org/10.1186/s13045-017-0393-3 |
_version_ | 1782496272248209408 |
---|---|
author | Poiré, Xavier Labopin, Myriam Maertens, Johan Yakoub-Agha, Ibrahim Blaise, Didier Ifrah, Norbert Socié, Gérard Gedde-Dhal, Tobias Schaap, Nicolaas Cornelissen, Jan J. Vigouroux, Stéphane Sanz, Jaime Michaux, Lucienne Esteve, Jordi Mohty, Mohamad Nagler, Arnon |
author_facet | Poiré, Xavier Labopin, Myriam Maertens, Johan Yakoub-Agha, Ibrahim Blaise, Didier Ifrah, Norbert Socié, Gérard Gedde-Dhal, Tobias Schaap, Nicolaas Cornelissen, Jan J. Vigouroux, Stéphane Sanz, Jaime Michaux, Lucienne Esteve, Jordi Mohty, Mohamad Nagler, Arnon |
author_sort | Poiré, Xavier |
collection | PubMed |
description | BACKGROUND: Acute myeloid leukaemia (AML) with 17p abnormalities (abn(17p)) carries a very poor prognosis due to high refractoriness to conventional chemotherapy, and allogeneic stem cell transplantation (allo-SCT) appears as the only potential curative option. METHODS: To address outcomes after allo-SCT in patients with abn(17p), we retrospectively analysed de novo or secondary AML undergoing SCT between 2000 and 2013 from the EBMT registry. RESULTS: One hundred thirty-nine patients with confirmed abn(17p) have been selected. At the time of transplant, one hundred twenty-five were in first remission (CR1). Median age was 54 years old. Abn(17p) was associated with a monosomal karyotype in 83% of patients, complex karyotype in 91%, monosomy 5 or 5q deletion (-5/5q-) in 55%, monosomy 7 (-7) in 39% and both -5/5q and -7 in 27%. Seventy-three patients (59%) had a reduced-intensity conditioning regimen. The 2-year overall survival (OS) and leukaemia-free survival (LFS) were 28 and 24%, respectively. The 2-year non-relapse mortality (NRM) was 15%, and 2-year relapse incidence (RI) was 61%. The cumulative incidence of grade II to IV acute graft-versus-host disease (GvHD) was 24% and that of chronic GvHD was 21%. In multivariate analysis, the presence of a -5/5q- in addition to abn(17p) was significantly and independently associated with worse OS, LFS and higher RI. Age and donor types did not correlate with outcome. Conditioning intensity was not statistically associated with OS, LFS and NRM when adjusted for patients’ age. CONCLUSIONS: In contrast to the dismal prognosis reported for AML patients harbouring abn(17p) undergoing conventional chemotherapy, allogeneic SCT provides responses in about 25% of those patients transplanted in CR1. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13045-017-0393-3) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5241968 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-52419682017-01-23 Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) Poiré, Xavier Labopin, Myriam Maertens, Johan Yakoub-Agha, Ibrahim Blaise, Didier Ifrah, Norbert Socié, Gérard Gedde-Dhal, Tobias Schaap, Nicolaas Cornelissen, Jan J. Vigouroux, Stéphane Sanz, Jaime Michaux, Lucienne Esteve, Jordi Mohty, Mohamad Nagler, Arnon J Hematol Oncol Research BACKGROUND: Acute myeloid leukaemia (AML) with 17p abnormalities (abn(17p)) carries a very poor prognosis due to high refractoriness to conventional chemotherapy, and allogeneic stem cell transplantation (allo-SCT) appears as the only potential curative option. METHODS: To address outcomes after allo-SCT in patients with abn(17p), we retrospectively analysed de novo or secondary AML undergoing SCT between 2000 and 2013 from the EBMT registry. RESULTS: One hundred thirty-nine patients with confirmed abn(17p) have been selected. At the time of transplant, one hundred twenty-five were in first remission (CR1). Median age was 54 years old. Abn(17p) was associated with a monosomal karyotype in 83% of patients, complex karyotype in 91%, monosomy 5 or 5q deletion (-5/5q-) in 55%, monosomy 7 (-7) in 39% and both -5/5q and -7 in 27%. Seventy-three patients (59%) had a reduced-intensity conditioning regimen. The 2-year overall survival (OS) and leukaemia-free survival (LFS) were 28 and 24%, respectively. The 2-year non-relapse mortality (NRM) was 15%, and 2-year relapse incidence (RI) was 61%. The cumulative incidence of grade II to IV acute graft-versus-host disease (GvHD) was 24% and that of chronic GvHD was 21%. In multivariate analysis, the presence of a -5/5q- in addition to abn(17p) was significantly and independently associated with worse OS, LFS and higher RI. Age and donor types did not correlate with outcome. Conditioning intensity was not statistically associated with OS, LFS and NRM when adjusted for patients’ age. CONCLUSIONS: In contrast to the dismal prognosis reported for AML patients harbouring abn(17p) undergoing conventional chemotherapy, allogeneic SCT provides responses in about 25% of those patients transplanted in CR1. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13045-017-0393-3) contains supplementary material, which is available to authorized users. BioMed Central 2017-01-18 /pmc/articles/PMC5241968/ /pubmed/28100265 http://dx.doi.org/10.1186/s13045-017-0393-3 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Poiré, Xavier Labopin, Myriam Maertens, Johan Yakoub-Agha, Ibrahim Blaise, Didier Ifrah, Norbert Socié, Gérard Gedde-Dhal, Tobias Schaap, Nicolaas Cornelissen, Jan J. Vigouroux, Stéphane Sanz, Jaime Michaux, Lucienne Esteve, Jordi Mohty, Mohamad Nagler, Arnon Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) |
title | Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) |
title_full | Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) |
title_fullStr | Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) |
title_full_unstemmed | Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) |
title_short | Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) |
title_sort | allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the acute leukemia working party (alwp) of the european society for blood and marrow transplantation (ebmt) |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241968/ https://www.ncbi.nlm.nih.gov/pubmed/28100265 http://dx.doi.org/10.1186/s13045-017-0393-3 |
work_keys_str_mv | AT poirexavier allogeneicstemcelltransplantationinadultpatientswithacutemyeloidleukaemiaand17pabnormalitiesinfirstcompleteremissionastudyfromtheacuteleukemiaworkingpartyalwpoftheeuropeansocietyforbloodandmarrowtransplantationebmt AT labopinmyriam allogeneicstemcelltransplantationinadultpatientswithacutemyeloidleukaemiaand17pabnormalitiesinfirstcompleteremissionastudyfromtheacuteleukemiaworkingpartyalwpoftheeuropeansocietyforbloodandmarrowtransplantationebmt AT maertensjohan allogeneicstemcelltransplantationinadultpatientswithacutemyeloidleukaemiaand17pabnormalitiesinfirstcompleteremissionastudyfromtheacuteleukemiaworkingpartyalwpoftheeuropeansocietyforbloodandmarrowtransplantationebmt AT yakoubaghaibrahim allogeneicstemcelltransplantationinadultpatientswithacutemyeloidleukaemiaand17pabnormalitiesinfirstcompleteremissionastudyfromtheacuteleukemiaworkingpartyalwpoftheeuropeansocietyforbloodandmarrowtransplantationebmt AT blaisedidier allogeneicstemcelltransplantationinadultpatientswithacutemyeloidleukaemiaand17pabnormalitiesinfirstcompleteremissionastudyfromtheacuteleukemiaworkingpartyalwpoftheeuropeansocietyforbloodandmarrowtransplantationebmt AT ifrahnorbert allogeneicstemcelltransplantationinadultpatientswithacutemyeloidleukaemiaand17pabnormalitiesinfirstcompleteremissionastudyfromtheacuteleukemiaworkingpartyalwpoftheeuropeansocietyforbloodandmarrowtransplantationebmt AT sociegerard allogeneicstemcelltransplantationinadultpatientswithacutemyeloidleukaemiaand17pabnormalitiesinfirstcompleteremissionastudyfromtheacuteleukemiaworkingpartyalwpoftheeuropeansocietyforbloodandmarrowtransplantationebmt AT geddedhaltobias allogeneicstemcelltransplantationinadultpatientswithacutemyeloidleukaemiaand17pabnormalitiesinfirstcompleteremissionastudyfromtheacuteleukemiaworkingpartyalwpoftheeuropeansocietyforbloodandmarrowtransplantationebmt AT schaapnicolaas allogeneicstemcelltransplantationinadultpatientswithacutemyeloidleukaemiaand17pabnormalitiesinfirstcompleteremissionastudyfromtheacuteleukemiaworkingpartyalwpoftheeuropeansocietyforbloodandmarrowtransplantationebmt AT cornelissenjanj allogeneicstemcelltransplantationinadultpatientswithacutemyeloidleukaemiaand17pabnormalitiesinfirstcompleteremissionastudyfromtheacuteleukemiaworkingpartyalwpoftheeuropeansocietyforbloodandmarrowtransplantationebmt AT vigourouxstephane allogeneicstemcelltransplantationinadultpatientswithacutemyeloidleukaemiaand17pabnormalitiesinfirstcompleteremissionastudyfromtheacuteleukemiaworkingpartyalwpoftheeuropeansocietyforbloodandmarrowtransplantationebmt AT sanzjaime allogeneicstemcelltransplantationinadultpatientswithacutemyeloidleukaemiaand17pabnormalitiesinfirstcompleteremissionastudyfromtheacuteleukemiaworkingpartyalwpoftheeuropeansocietyforbloodandmarrowtransplantationebmt AT michauxlucienne allogeneicstemcelltransplantationinadultpatientswithacutemyeloidleukaemiaand17pabnormalitiesinfirstcompleteremissionastudyfromtheacuteleukemiaworkingpartyalwpoftheeuropeansocietyforbloodandmarrowtransplantationebmt AT estevejordi allogeneicstemcelltransplantationinadultpatientswithacutemyeloidleukaemiaand17pabnormalitiesinfirstcompleteremissionastudyfromtheacuteleukemiaworkingpartyalwpoftheeuropeansocietyforbloodandmarrowtransplantationebmt AT mohtymohamad allogeneicstemcelltransplantationinadultpatientswithacutemyeloidleukaemiaand17pabnormalitiesinfirstcompleteremissionastudyfromtheacuteleukemiaworkingpartyalwpoftheeuropeansocietyforbloodandmarrowtransplantationebmt AT naglerarnon allogeneicstemcelltransplantationinadultpatientswithacutemyeloidleukaemiaand17pabnormalitiesinfirstcompleteremissionastudyfromtheacuteleukemiaworkingpartyalwpoftheeuropeansocietyforbloodandmarrowtransplantationebmt |